Literature DB >> 26071284

Routine genotyping of patients on clopidogrel: Why the resistance?

Ganesan Karthikeyan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26071284      PMCID： PMC4475837          DOI： 10.1016/j.ihj.2015.04.008

Source DB:  PubMed          Journal:  Indian Heart J        ISSN： 0019-4832


× No keyword cloud information.
  12 in total

1.  Pharmacogenomics and clopidogrel: irrational exuberance?

Authors:  Steven E Nissen
Journal:  JAMA       Date:  2011-12-28       Impact factor: 56.272

2.  ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association.

Authors:  David R Holmes; Gregory J Dehmer; Sanjay Kaul; Dana Leifer; Patrick T O'Gara; C Michael Stein
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

Review 3.  CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.

Authors:  Michael V Holmes; Pablo Perel; Tina Shah; Aroon D Hingorani; Juan P Casas
Journal:  JAMA       Date:  2011-12-28       Impact factor: 56.272

4.  Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

Authors:  Matthew J Price; Peter B Berger; Paul S Teirstein; Jean-François Tanguay; Dominick J Angiolillo; Douglas Spriggs; Sanjeev Puri; Mark Robbins; Kirk N Garratt; Olivier F Bertrand; Michael E Stillabower; Michael E Stillablower; Joseph R Aragon; David E Kandzari; Curtiss T Stinis; Michael S Lee; Steven V Manoukian; Christopher P Cannon; Nicholas J Schork; Eric J Topol
Journal:  JAMA       Date:  2011-03-16       Impact factor: 56.272

5.  Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Joseph R Walker; Tabassome Simon; Elliott M Antman; Eugene Braunwald; Marc S Sabatine
Journal:  Lancet       Date:  2010-10-16       Impact factor: 79.321

6.  Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.

Authors:  Lars Wallentin; Stefan James; Robert F Storey; Martin Armstrong; Bryan J Barratt; Jay Horrow; Steen Husted; Hugo Katus; P Gabriel Steg; Svati H Shah; Richard C Becker
Journal:  Lancet       Date:  2010-10-16       Impact factor: 79.321

Review 7.  Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.

Authors:  Betti Giusti; Anna Maria Gori; Rossella Marcucci; Rosanna Abbate
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-04       Impact factor: 4.481

8.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.

Authors:  Alan R Shuldiner; Jeffrey R O'Connell; Kevin P Bliden; Amish Gandhi; Kathleen Ryan; Richard B Horenstein; Coleen M Damcott; Ruth Pakyz; Udaya S Tantry; Quince Gibson; Toni I Pollin; Wendy Post; Afshin Parsa; Braxton D Mitchell; Nauder Faraday; William Herzog; Paul A Gurbel
Journal:  JAMA       Date:  2009-08-26       Impact factor: 56.272

9.  Cytochrome p-450 polymorphisms and response to clopidogrel.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

10.  Bedside monitoring to adjust antiplatelet therapy for coronary stenting.

Authors:  Jean-Philippe Collet; Thomas Cuisset; Grégoire Rangé; Guillaume Cayla; Simon Elhadad; Christophe Pouillot; Patrick Henry; Pascal Motreff; Didier Carrié; Ziad Boueri; Loic Belle; Eric Van Belle; Hélène Rousseau; Pierre Aubry; Jacques Monségu; Pierre Sabouret; Stephen A O'Connor; Jérémie Abtan; Mathieu Kerneis; Christophe Saint-Etienne; Olivier Barthélémy; Farzin Beygui; Johanne Silvain; Eric Vicaut; Gilles Montalescot
Journal:  N Engl J Med       Date:  2012-11-04       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.